Haynes Capital Corp. Hosts Professor Darren Shafren and Dr. Stephen Lambros of Viralytics Ltd.

    TORONTO, March 13 /CNW/ - Haynes Capital Corp. will host a dinner
presentation by Professor Darren Shafren of the University of Newcastle and Dr
Stephen Lambros, Chief Medical Officer of Viralytics Ltd (OTC:VRACY)(ASX:VLA),
on the evening of March 13, 2007.

    Viralytics is an Australian Biotechnology company developing a set of
natural Viruses that have cancer cell infecting properties. This therapeutic
approach is referred to as Oncolytic Virotherapy. Professor Shafren discovered
the viruses' properties and published his findings in Clinical Cancer
Research, in January 2004. The paper can be read in full at:


    "Oncolytic Virotherapy is gaining momentum as a new approach to the
treatment of Cancer. Viruses cause tissue destruction by their infection.
Oncolytic Viruses have a mechanism by which the virus can preferentially
infect cancer cells, and this mechanism varies between virus types. The
Oncolytic Viruses we are developing at Viralytics, take advantage of a natural
property of the virus to attach to proteins that are overexpressed on cancer
cells. Our lead virus is Coxsackievirus type A21. It has been known to
medicine for over 50 years, and has been associated with the common cold, and
produces mild infections that are self limited, in other words you recover
easily without significant harm when you have a natural infection with this
virus. However when the virus is exposed to cancer cells, it changes
character, and produces an infection that is quite destructive in the cancer
cells, whether these cells are growing in a culture medium, or growing in
animal model tumors," states Dr. Lambros.

    "The receptors required by the set of viruses we are developing, are
highly expressed on multiple cancer types. Our initial trial will be in
melanoma. Other cancers that may be susceptible due to this over-expression of
receptors the virus uses include Prostate, Breast and Ovarian cancers, as well
as Multiple Myeloma. Much work remains, of course, to properly investigate
these viruses in trials, however we will be getting some indication as to
their effect in late stage melanoma patients' tumors over the coming months,"
Dr. Lambros further reported.

    Viralytics has been assigned the Global Marketing rights to the viruses,
and is preparing for a Phase I trial in late stage Melanoma patients to
commence shortly in Australia.

    As announced earlier the event, which will include a presentation
followed by an open question and answer session, will be held at The Spoke
Club, a private club located at 600 King Street West in downtown Toronto,

    Individuals and organizations interested in attending this event should
contact Mr. Brent O'Connor via email brent@haynescapital.com or telephone

    About Viralytics Ltd.

    Viralytics is listed on the Australian Stock Exchange (ASX code: VLA),
located in Sydney Australia. Viralytics ADR trades under VRACY on the OTC
market in the USA. Viralytics' principal asset is the intellectual property
relating to CAVATAK(TM), an Oncolytic Virus technology. CAVATAK(TM) is the
trade name for Viralytics' proprietary formulation of the Coxsackievirus Type
A21 (CVA21). www.viralytics.com

    About Haynes Capital Corp.

    Haynes Capital Corp. is a capital management company that provides access
to the investment community. Services include corporate finance strategies,
investor awareness programs and strategic business development. For more
information on Haynes Capital visit www.haynescapital.com.

For further information:

For further information: Haynes Capital Corp. Mr. Brent O'Connor,
1-866-507-0481 (Investor Relations) brent@haynescapital.com

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890